Posted: Monday, June 20, 2022
For patients with relapsed or refractory large B-cell lymphoma (LBCL) not intended for hematopoietic stem cell transplantation (HSCT), use of the CD19-directed chimeric antigen receptor T-cell product lisocabtagene maraleucel may serve as a potential second-line treatment, according to the results of the phase II pilot study presented at the European Hematology Association (EHA) 2022 Hybrid Congress (Abstract P1710). The use of lisocabtagene maraleucel resulted in significantly improved patient scores on the Functional Assessment of Cancer Therapy–Lymphoma Subscale (FACT-LymS) with no apparent negative impact on quality of life, according to Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center, Chicago, and colleagues.
Patients with relapsed or refractory LBCL who had received first-line treatment were recruited for the study. All patients were required to complete the FACT-LymS, the EQ-5D-5L health utility index (HUI), the European Organisation for Research and Treatment of Cancer Quality-of-Life-Questionnaire (EORTC QLQ-C30), and the visual analog scale questionnaire. These questionnaires were completed at baseline, before treatment, during treatment, and on multiple days after treatment.
At baseline, fatigue was worse than in the general population on the EORTC QLQ-C30. After treatment and through day 545, the overall least-squares mean changes demonstrated significant improvement in loss of appetite, fatigue, and pain, as calculated on the EORTC QLQ-C30. These improvements were also seen on the EQ visual analog scale questionnaire and the FACT-LymS. Furthermore, results from the EORTC QLQ-C30 at 6 months revealed a clinically significant improvement in quality of life (93%), role functioning (90%), fatigue (87%), cognitive functioning (83%), physical functioning (80%), and pain (80%), the investigators reported.
Disclosure: For full disclosures of the study authors, visit library.ehaweb.org.